James William Denham: Influence Statistics

James William Denham

James William Denham

University of Newcastle, Callaghan, Australia; | School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia | Calvary Mater New Castle, Waratah, ...


Download all Influence Scores

James William Denham: Expert Impact

Concepts for which James William Denham has direct influence: Prostate cancer , Zoledronic acid , Androgen suppression , Radiation therapy , Urinary symptoms , Urinary dysfunction , Biochemical failure .

James William Denham: KOL impact

Concepts related to the work of other authors for which for which James William Denham has influence: Prostate cancer , Radiation therapy , Androgen deprivation , Squamous cell , Quality life , Head neck .

KOL Resume for James William Denham

Year
2022

University of Newcastle, Callaghan, Australia;

2021

School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia

2020

School of Medicine and Public Health, University of Newcastle, Callaghan, Australia.

Newcastle Calvary Mater Hospital, Waratah, NSW, Australia

2019

School of Mathematical and Physical Sciences, University of Newcastle, Newcastle, NSW, Australia

2018

Newcastle Mater Hospital, Newcastle, NSW, Australia

2017

Newcastle Mater Hospital Newcastle NSW Australia

Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, AUSTRALIA.

2016

School of Medicine and Population Health, University of Newcastle, University Drive, Callaghan, NSW 2308 Australia

2015

University of Newcastle School of Medicine and Public Health Newcastle New South Wales Australia

2014

Faculty of Health and Medicine, Prostate Cancer Trials Group, School of Medicine and Public Health, University of Newcastle, NSW, Australia

2013

School of Medicine and Public Health, The University of Newcastle, Australia

2012

Department of Radiation Oncology, Calvary Mater Newcastle, Locked Bag 7, Hunter Region Mail Centre, NSW 2310, Australia

2011

Calvary Mater Hospital, Newcastle, Australia

University of Newcastle, Newcastle, NSW.

2010

Radiation Oncology Department, Calvary Mater Hospital, Waratah, NSW 2298, Australia

Newcastle Prostate Cancer Centre and University of Newcastle, New South Wales

2009

School of Medicine and Public Health, the University of Newcastle, Newcastle, New South Wales, Australia

Departments of Radiation Oncology and

2008

University of Newcastle

2007

Trans-Tasman Radiation Oncology Group, Newcastle Mater Hospital, Newcastle, New South Wales

Department of Radiation Oncology, Vancouver Island Cancer Center, Victoria, British Columbia, Canada

Radiation Oncology, Mater Hospital, University of Newcastle, Australia, Locked Bag 7, Newcastle, Callaghan NSW, Australia

Princess Margaret Hospital, Toronto, Ontario

2006

Division of Medicine, University of Newcastle, 2038, Callaghan, NSW, Australia

2005

Department of Radiation Oncology, QRI-Royal Brisbane Hospital, Brisbane

Newcastle Mater Hospital, Newcastle, New South Wales, Australia

From the Division of Haematology and Medical Oncology, Division of Radiation Oncology, and Statistical Centre, Peter MacCallum Cancer Centre, Melbourne

Prominent publications by James William Denham

KOL-Index: 27253 . BACKGROUND: We investigated whether 18 months of androgen suppression plus radiotherapy, with or without 18 months of zoledronic acid, is more effective than 6 months of neoadjuvant androgen suppression plus radiotherapy with or without zoledronic acid. METHODS: We did an open-label, randomised, 2 × 2 factorial trial in men with locally advanced prostate cancer (either T2a N0 M0 prostatic ...
Known for Zoledronic Acid | Androgen Suppression | Gleason Score | Prostate Cancer
KOL-Index: 25311 . BACKGROUND: Adjuvant androgen suppression and bisphosphonates with escalating doses of radiotherapy might improve efficacy outcomes in men with locally advanced prostate cancer. In this study, we investigated whether these treatments had a detrimental effect on patient-reported-outcome (PRO) scores. METHODS: We undertook a phase 3 trial with a 2×2 factorial design in 23 centres in ...
Known for Zoledronic Acid | 18 Months | Prostate Cancer | Stas Itas
KOL-Index: 19905 . BACKGROUND: The optimal duration of androgen suppression for men with locally advanced prostate cancer receiving radiotherapy with curative intent is yet to be defined. Zoledronic acid is effective in preventing androgen suppression-induced bone loss, but its role in preventing castration-sensitive bone metastases in locally advanced prostate cancer is unclear. The RADAR trial assessed ...
Known for Zoledronic Acid | Androgen Suppression | Prostate Cancer | 18 Months
KOL-Index: 16821 . BACKGROUND: The TROG 96.01 trial assessed whether 3-month and 6-month short-term neoadjuvant androgen deprivation therapy (NADT) decreases clinical progression and mortality after radiotherapy for locally advanced prostate cancer. Here we report the 10-year results. METHODS: Between June, 1996, and February, 2000, 818 men with T2b, T2c, T3, and T4 N0 M0 prostate cancers were randomly ...
Known for Neoadjuvant Androgen | Prostate Cancer | 6 Months | Neoplasms Radiotherapy
KOL-Index: 14393 . PURPOSE: To select one of two chemoradiotherapy regimens for locally advanced squamous cell carcinoma (SCC) of the head and neck as the experimental arm for the next Trans-Tasman Radiation Oncology Group phase III trial. PATIENTS AND METHODS: One hundred twenty-two previously untreated patients with stage III/IV SCC of the head and neck were randomized to receive definitive radiotherapy ...
Known for Tpz Cis | Neck Cancer | Locally Advanced Head | Radiation Oncology
KOL-Index: 14373 . BACKGROUND: Long-term prostate cancer (PCa) survivors are at increased risk for comorbidities and physical deconditioning. OBJECTIVE: To determine the effectiveness of a year-long randomised controlled trial of exercise training in PCa survivors >5 yr postdiagnosis on physical functioning. DESIGN, SETTING, AND PARTICIPANTS: Between 2010 and 2011, 100 long-term PCa survivors from ...
Known for Physical Function | Exercise Training | Androgen Suppression | Muscle Strength
KOL-Index: 13871 . PURPOSE: Prostate radiation therapy dose planning directly on magnetic resonance imaging (MRI) scans would reduce costs and uncertainties due to multimodality image registration. Adaptive planning using a combined MRI-linear accelerator approach will also require dose calculations to be performed using MRI data. The aim of this work was to develop an atlas-based method to map realistic ...
Known for Based Prostate | Resonance Imaging | Electron Density | Mri Scans
KOL-Index: 13112 . BACKGROUND: The Meta-Analysis of Radiotherapy in squamous cell Carcinomas of Head and neck (MARCH) showed that altered fractionation radiotherapy is associated with improved overall and progression-free survival compared with conventional radiotherapy, with hyperfractionated radiotherapy showing the greatest benefit. This update aims to confirm and explain the superiority of ...
Known for Fractionation Radiotherapy | Head Neck | Concomitant Chemotherapy | 10 Years
KOL-Index: 13104 . PURPOSE: The aims of this randomized controlled trial were to determine whether there were differences in the disease-free survival (DFS) and toxicity between conventional radiotherapy (CRT) and a continuous 3 week accelerated radiotherapy regimen (ART) in stage III and IV squamous cell carcinoma of the oral cavity, oropharynx, larynx and hypopharynx. PATIENTS AND METHODS: Patients from 14 ...
Known for Conventional Radiotherapy | Stage Iii | Randomised Trial | Late Effects
KOL-Index: 13091 . BACKGROUND: Androgen suppression therapy and radiotherapy are used to treat locally advanced prostate cancer. 3 years of androgen suppression confers a small survival benefit compared with 6 months of therapy in this setting, but is associated with more toxic effects. Early identification of men in whom radiotherapy and 6 months of androgen suppression is insufficient for cure is ...
Known for Androgen Suppression | Prostate Cancer | 6 Months | Surrogate Endpoints
KOL-Index: 12772 . BACKGROUND: Androgen deprivation is an established treatment regimen for disseminated prostate cancer; however, its role in patients with localised cancer is less clear. We did a large randomised controlled trial to determine whether 3 months or 6 months of androgen deprivation given before and during radiotherapy improves outcomes for patients with locally advanced prostate ...
Known for Androgen Deprivation | Advanced Prostate | Diseasefree Survival | Salvage Treatment
KOL-Index: 11630 . BACKGROUND: Surrogate endpoints for prostate cancer-specific mortality after curative primary treatment are not well established. We sought to assess time to biochemical failure (TTBF) and prostate-specific antigen doubling time (PSADT) after failure of curative treatment as candidates for this endpoint. METHODS: PSA and survival data from the Trans-Tasman Radiation Oncology Group (TROG) ...
Known for Biochemical Failure | Specific Mortality | Prostate Cancer | Time Psadt
KOL-Index: 11316 . BACKGROUND AND PURPOSE: A limited number of studies have suggested that oral sucralfate reduces the acute and late gastro-intestinal side-effects of pelvic radiotherapy and sucralfate enemas ameliorate symptoms of chronic proctitis. Sucralfate may act via local bFGF at the mucosal level in promoting angiogenesis and reducing epithelial associated microvascular injury. This ...
Known for Acute Radiation | Rectal Sucralfate | Daily Enema | Randomised Study
KOL-Index: 11309 . BACKGROUND: Resection remains the best treatment for carcinoma of the oesophagus in terms of local control, but local recurrence and distant metastasis remain an issue after surgery. We aimed to assess whether a short preoperative chemoradiotherapy regimen improves outcomes for patients with resectable oesophageal cancer. METHODS: 128 patients were randomly assigned to surgery alone and ...
Known for Chemoradiotherapy Surgery | Progressionfree Survival | Resectable Oesophageal Cancer | Subgroup Analysis Patients

Key People For Prostate Cancer

Top KOLs in the world
#1
Ahmedin M Jemal
united states breast cancer addis ababa
#2
Peter T Scardino
prostate cancer active surveillance erectile function
#3
Rebecca L Siegel
united states colorectal cancer incidence rates
#4
Johnathan I Jonathan
prostate cancer gleason score needle biopsy
#5
Philip W Kantoff
prostate cancer psma adc androgen deprivation therapy
#6
PATRICK CRAIG Walsh
prostate cancer specific antigen pathological stage

University of Newcastle, Callaghan, Australia; | School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia | Calvary Mater New Castle, Waratah, NSW, Australia | School of Medicine and Population Health, University of Ne